Stem Cell Therapeutics Announces Issuance of Keystone Prolactin Patents
07 July 2008 - 11:00PM
Marketwired
CALGARY, ALBERTA (TSX VENTURE: SSS) is pleased to announce the
Company has been issued two corresponding patents to strengthen its
intellectual property landscape through United States and
Australia.
The U.S. patent, numbered 7,393,830 and entitled "Prolactin
induced increase in neural stem cell numbers" was issued July 1,
2008. The Australian patent, numbered 2002325711 and entitled
"Prolactin induced increase in neural stem cell numbers and
therapeutical use thereof" was issued January 10, 2008. These are
the first patents to issue in this patent family.
Dr. Alan Moore, President and CEO of SCT commented as
follows:
"What is particularly important about these patents is that they
cover the use of prolactin alone, as well as in combination with
other therapeutics that augment recovery and therefore provide a
broad base of protection. We have the exclusive right to the use of
prolactin for treating neurodegenerative diseases and therefore
have a strong foundation to develop many possible products using
prolactin, either as a single therapeutic or in combination with
other neurogenic agents. For example, this intellectual property
supports programs currently under development using prolactin alone
or with anti-inflammatories to treat multiple sclerosis and using a
combination of prolactin and EPO to treat other neurodegenerative
diseases."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The company's programs aim to
repair neurological function lost due to disease or injury. The
company's extensive patent portfolio of owned and licensed
intellectual property supports the potential expansion into future
clinical programs in numerous neurological diseases such as
traumatic brain injury and multiple sclerosis. SCT is currently
recruiting patients for the multi-centre, double-blind,
placebo-controlled REGENESIS Phase IIb acute stroke study for its
lead program, NTx(TM)-265, with primary endpoints of efficacy.
Patient enrolment is expected to be complete by the end of 2008
with top-line efficacy data expected to be released before the end
of the first quarter of 2009.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
(403) 245-5495 ext. 221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024